AR076892A1 - Conjugados de albumina-peptido amiloide y usos de los mismos - Google Patents
Conjugados de albumina-peptido amiloide y usos de los mismosInfo
- Publication number
- AR076892A1 AR076892A1 ARP100101822A ARP100101822A AR076892A1 AR 076892 A1 AR076892 A1 AR 076892A1 AR P100101822 A ARP100101822 A AR P100101822A AR P100101822 A ARP100101822 A AR P100101822A AR 076892 A1 AR076892 A1 AR 076892A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugates
- amiloide
- albumina
- peptido
- same
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen conjugados que comprenden albumina y un péptido derivado de la region C-terminal de péptido beta-amiloide, así como usos de los mismos para el tratamiento de enfermedades caracterizadas por la deposicion de proteínas amiloides y, en particular, para el tratamiento de la enfermedad de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382078A EP2258398A1 (en) | 2009-05-26 | 2009-05-26 | Albumin-amyloid peptide conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076892A1 true AR076892A1 (es) | 2011-07-13 |
Family
ID=41022577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101822A AR076892A1 (es) | 2009-05-26 | 2010-05-26 | Conjugados de albumina-peptido amiloide y usos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9023991B2 (es) |
| EP (2) | EP2258398A1 (es) |
| JP (2) | JP5936539B2 (es) |
| KR (1) | KR101459080B1 (es) |
| CN (1) | CN102458478B (es) |
| AR (1) | AR076892A1 (es) |
| AU (1) | AU2010251961B2 (es) |
| BR (1) | BRPI1011314A2 (es) |
| CA (1) | CA2763569C (es) |
| DK (1) | DK2435093T3 (es) |
| ES (1) | ES2587962T3 (es) |
| HU (1) | HUE030218T2 (es) |
| IL (1) | IL216626A (es) |
| MX (1) | MX2011012677A (es) |
| PL (1) | PL2435093T3 (es) |
| PT (1) | PT2435093T (es) |
| RU (1) | RU2533806C2 (es) |
| TW (1) | TWI524900B (es) |
| WO (1) | WO2010136487A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013021353A1 (en) * | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| CN103450347A (zh) * | 2012-05-29 | 2013-12-18 | 四川百利药业有限责任公司 | 一种用于治疗阿尔兹海默症的多肽及基因疫苗 |
| CN105315361A (zh) * | 2014-07-29 | 2016-02-10 | 天津大学 | 一种酸化白蛋白及制备方法和在抑制β-淀粉样蛋白聚集的应用 |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN115715809A (zh) * | 2022-11-24 | 2023-02-28 | 武汉禾元生物科技股份有限公司 | 重组人血清白蛋白-药物偶联物 |
| KR20250125186A (ko) * | 2024-02-14 | 2025-08-21 | 국립부경대학교 산학협력단 | 알부민 고정 셀룰로오스 및 이를 포함하는 알츠하이머 치료용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| EP1308461A3 (en) * | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| CA2286305A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| US6809186B1 (en) | 1999-01-22 | 2004-10-26 | Martek Biosciences Corporation | Simple method for labeled conjugate production |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| EA008762B1 (ru) | 2000-02-21 | 2007-08-31 | Фармекса А/С | АНАЛОГ АУТОЛОГИЧНОГО Аβ ИЛИ АРР ЖИВОТНОГО И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| EP1803730A1 (en) * | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6787636B1 (en) | 2000-07-14 | 2004-09-07 | New Century Pharmaceuticals, Inc. | Modified serum albumin with reduced affinity for nickel and copper |
| EP1975179A1 (en) * | 2001-12-26 | 2008-10-01 | Araclon Biotech, S.L. | Polyclonal antibodies, preparation method thereof and use of same |
| US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| AU2003259965A1 (en) | 2002-08-20 | 2004-03-11 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2246177B1 (es) * | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| MY144231A (en) * | 2003-12-17 | 2011-08-15 | Wyeth Corp | Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
| EP1696962A2 (en) | 2003-12-18 | 2006-09-06 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| EP1711208A2 (en) * | 2004-01-28 | 2006-10-18 | Curix APS | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
| JP4980895B2 (ja) | 2004-05-25 | 2012-07-18 | メディミューン，エルエルシー | インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 |
| AU2006232920B2 (en) | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| CA2607868A1 (en) * | 2005-05-05 | 2006-11-16 | Merck & Co., Inc. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| JP5231231B2 (ja) | 2005-10-19 | 2013-07-10 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用 |
| US8106015B2 (en) * | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
-
2009
- 2009-05-26 EP EP09382078A patent/EP2258398A1/en not_active Withdrawn
-
2010
- 2010-05-26 PL PL10724360.2T patent/PL2435093T3/pl unknown
- 2010-05-26 US US13/322,417 patent/US9023991B2/en active Active
- 2010-05-26 KR KR1020117031061A patent/KR101459080B1/ko not_active Expired - Fee Related
- 2010-05-26 CA CA2763569A patent/CA2763569C/en not_active Expired - Fee Related
- 2010-05-26 HU HUE10724360A patent/HUE030218T2/en unknown
- 2010-05-26 MX MX2011012677A patent/MX2011012677A/es active IP Right Grant
- 2010-05-26 JP JP2012512356A patent/JP5936539B2/ja not_active Expired - Fee Related
- 2010-05-26 TW TW099116941A patent/TWI524900B/zh not_active IP Right Cessation
- 2010-05-26 ES ES10724360.2T patent/ES2587962T3/es active Active
- 2010-05-26 RU RU2011153023/10A patent/RU2533806C2/ru active
- 2010-05-26 EP EP10724360.2A patent/EP2435093B1/en active Active
- 2010-05-26 WO PCT/EP2010/057235 patent/WO2010136487A1/en not_active Ceased
- 2010-05-26 AU AU2010251961A patent/AU2010251961B2/en not_active Ceased
- 2010-05-26 BR BRPI1011314A patent/BRPI1011314A2/pt not_active Application Discontinuation
- 2010-05-26 DK DK10724360.2T patent/DK2435093T3/en active
- 2010-05-26 AR ARP100101822A patent/AR076892A1/es not_active Application Discontinuation
- 2010-05-26 PT PT107243602T patent/PT2435093T/pt unknown
- 2010-05-26 CN CN201080031742.0A patent/CN102458478B/zh not_active Expired - Fee Related
-
2011
- 2011-11-27 IL IL216626A patent/IL216626A/en active IP Right Grant
-
2013
- 2013-09-20 US US14/032,830 patent/US9163062B2/en active Active
-
2014
- 2014-11-21 JP JP2014237014A patent/JP5985589B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076892A1 (es) | Conjugados de albumina-peptido amiloide y usos de los mismos | |
| EA201171388A1 (ru) | Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида | |
| CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR083561A1 (es) | Preparacion de una construccion antigenica | |
| CO6571908A2 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedaded inmunes y autoinmunes | |
| MX2018011836A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
| BR112017012377A2 (pt) | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula | |
| GT201300131A (es) | Metodos de tratamiento de trastornos asociados con el fgf21 | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| MX2014003677A (es) | Proteinas de fusion para el tratamiento de trastornos metabolicos. | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
| BRPI1006116A2 (pt) | "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes". | |
| PE20150201A1 (es) | Proteinas del factor 21 de crecimiento del fibroblasto | |
| AR077764A1 (es) | Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos | |
| BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
| UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
| BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| GT201200123A (es) | Nuevo uso antitumoral de cabazitaxel | |
| PE20151603A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos | |
| CO6741197A2 (es) | Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma | |
| DOP2012000232A (es) | Proteínas de unión a antigeno especificas para el componente amiloide serico p | |
| AR096123A1 (es) | Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |